Perioperative Immunotherapy in Muscle-invasive Bladder Cancer

Abhishek Tripathi; Ali Raza Khaki; Petros Grivas

doi:10.1016/j.euo.2021.01.004

Perioperative Immunotherapy in Muscle-invasive Bladder Cancer

Eur Urol Oncol. 2021 Apr;4(2):131-133. doi: 10.1016/j.euo.2021.01.004. Epub 2021 Feb 26.

Authors

Abhishek Tripathi¹, Ali Raza Khaki², Petros Grivas³

Affiliations

¹ Department of Medicine, Section of Hematology Oncology, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.
² Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
³ Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA. Electronic address: pgrivas@uw.edu.

PMID: 33642222
DOI: 10.1016/j.euo.2021.01.004

Abstract

Immune checkpoint inhibitors (ICIs) have already been approved for the treatment of metastatic urothelial carcinoma and are now being investigated for perioperative treatment of muscle-invasive bladder cancer (MIBC). Ongoing trials are assessing ICIs as monotherapy and in combination with other treatments. Early data are promising, and long-term survival data are awaited to confirm the potential of ICIs in MIBC.

Publication types

Editorial

MeSH terms

Carcinoma, Transitional Cell* / therapy
Humans
Immunotherapy
Muscles
Urinary Bladder Neoplasms* / therapy

Grants and funding

T32 CA009515/CA/NCI NIH HHS/United States